参考资料:
[1] Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy. Retrieved June 10, 2024, from https://www.globenewswire.com/news-release/2024/06/10/2895804/0/en/Oculis-Announces-Positive-Topline-Results-of-Phase-2b-RELIEF-Trial-with-Licaminlimab-Designed-to-Transform-the-Treatment-Paradigm-of-Dry-Eye-Disease-with-a-Precision-Medicine-Strat.html
[2] US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk. Retrieved June 10, 2024, from https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/